EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing…
8,208€
0,28%
Echtzeit-Aktienkurs EyePoint Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur EyePoint Pharmaceuticals Inc. Aktie
EyePoint Pharmaceuticals stock sinks following clinical trial results By Investing.com
EyePoint Pharmaceuticals stock sinks following clinical trial results…
EyePoint Pharmaceuticals: Mit DURAVYU könnte man 40 % der Marktanteile im wAMD-Segment gewinnen!
EyePoint Pharmaceuticals Inc. (EYPT) hat sich auf Therapien zur Behandlung schwerer Netzhauterkrankungen spezialisiert. Im Fokus stehen zum Beispiel Lösungen für…
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
…
EyePoint Pharmaceuticals prices $140M share offering
…
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…
EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…
EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To Buy The Dip (Rating Upgrade)
…
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…
Cormorant Asset Management buys $10.49m in EyePoint Pharmaceuticals shares By Investing.com
Cormorant Asset Management buys $10.49m in EyePoint Pharmaceuticals shares…
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…
Earnings call: EyePoint Pharmaceuticals outlines growth and EYP-1901 progress By Investing.com
Earnings call: EyePoint Pharmaceuticals outlines growth and EYP-1901 progress…
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcript
…
EyePoint Pharmaceuticals appoints new Chief Medical Officer By Investing.com
EyePoint Pharmaceuticals appoints new Chief Medical Officer…